암 종양 프로파일링 시장 규모, 점유율, 성장 분석, 암 유형별, 바이오마커 유형별, 기술별, 방법별, 용도별, 지역별 - 산업 예측(2025-2032년)
Cancer Tumor Profiling Market Size, Share, and Growth Analysis, By Cancer type (Breast Cancer, Lung Cancer), By Biomarker type (Genomic Biomarker, Protein Biomarker), By Technology, By Technique, By Application, By Region - Industry Forecast 2025-2032
상품코드:1663018
리서치사:SkyQuest
발행일:2025년 02월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
암 종양 프로파일링 세계 시장 규모는 2023년에 121억 달러로 평가되었습니다. 2024년 134억 4,000만 달러에서 2032년에는 312억 달러로 성장할 것으로 예상되며, 예측 기간(2025-2032년) 동안 11.1%의 연평균 복합 성장률(CAGR)을 보일 전망입니다.
세계 암 진단 및 치료 시장은 암 유병률 증가와 종양 프로파일링에서 바이오마커의 사용 증가로 인해 강화되고 있습니다. 연구 자금 증가와 기술 발전은 암 및 종양 프로파일링 분야의 성장을 가속하고 있습니다. 또한, 개인 맞춤형 의료 및 현장 진단을 향한 추세는 향후 몇 년동안 시장 진출기업들에게 큰 비즈니스 기회를 창출할 것으로 예상되며, 코로나19 팬데믹은 초기에는 암 검사 및 진단에 혼란을 가져왔지만, 전체 시장은 회복력을 유지했습니다. 예측 기간 동안 유전체학, 단백질체학, 후성유전학, 대사체학을 포함한 암/종양 프로파일링 분야가 성장할 것으로 예상되며, 특히 유전체학은 19.7%의 연평균 복합 성장률(CAGR)로 가장 높은 성장률을 나타낼 것으로 예상되며, 암의 회복력과 진행과 관련된 유전자 이상 규명에서 혁신을 촉진할 것으로 예상됩니다. 혁신을 촉진할 것입니다.
목차
서론
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter의 Five Forces 분석
주요 시장 인사이트
중요 성공 요인
경쟁 정도
주요 투자 기회
시장 생태계
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
암 종양 프로파일링 시장 규모 : 암 유형별
시장 개요
유방암
폐암
대장암
전립선암
흑색종암
기타 암
암 종양 프로파일링 시장 규모 : 바이오마커 유형별
시장 개요
유전체 바이오마커
단백질 바이오마커
암 종양 프로파일링 시장 규모 : 기술별
시장 개요
면역측정
차세대 시퀀싱
중합효소 연쇄반응
질량분석
In-Situ Hybridization
마이크로어레이
기타
암 종양 프로파일링 시장 규모 : 방법별
시장 개요
유전체학
단백질체학
대사체학
에피제네틱스
암 종양 프로파일링 시장 규모 : 용도별
시장 개요
조사
바이오마커 탐색
맞춤형 의료
임상 응용
진단
예측
스크리닝
치료 및 모니터링
암 종양 프로파일링 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
주요 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
전년대비 매출 비교(2022-2024년)
주요 기업 개요
Illumina, Inc.(USA)
QIAGEN N.V.(Netherlands)
NeoGenomics, Inc.(USA)
Thermo Fisher Scientific(USA)
Roche Diagnostics(Switzerland)
Guardant Health, Inc.(USA)
Foundation Medicine, Inc.(USA)
Sysmex Corporation(Japan)
Becton, Dickinson and Company(BD)(USA)
F. Hoffmann-La Roche Ltd.(Switzerland)
Merck & Co., Inc.(USA)
Pfizer Inc.(USA)
Novartis AG(Switzerland)
AstraZeneca(UK)
Bristol-Myers Squibb Company(USA)
Johnson & Johnson(USA)
Danaher Corporation(USA)
Abbott Laboratories(USA)
결론과 제안
LSH
영문 목차
영문목차
Global Cancer Tumor Profiling Market size was valued at USD 12.1 billion in 2023 and is poised to grow from USD 13.44 billion in 2024 to USD 31.2 billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).
The global cancer detection and treatment market is bolstered by the rising prevalence of cancer and the increasing utilization of biomarkers in tumor profiling. Enhanced research funding and technological advancements are fueling growth in the cancer and tumor profiling sectors. Furthermore, the trend towards personalized medicine and point-of-care diagnostics is anticipated to create substantial opportunities for market participants in the coming years. While the COVID-19 pandemic initially disrupted cancer testing and diagnosis, the overall market remained resilient. During the forecast period, cancer/tumor profiling segments encompassing genomics, proteomics, epigenetics, and metabolomics are expected to thrive, with genomics projected to achieve the highest CAGR of 19.7%, driving innovations in understanding gene abnormalities connected to cancer resilience and progression.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Tumor Profiling market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cancer Tumor Profiling Market Segments Analysis
Global Cancer Tumor Profiling Market is segmented by Cancer type, Biomarker type, Technology, Technique, Application and region. Based on Cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer. Based on Biomarker type, the market is segmented into Genomic Biomarker and Protein Biomarker. Based on Technology, the market is segmented into Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays and Others. Based on Technique, the market is segmented into Genomics, Proteomics, Metabolomics and Epigenetics. Based on Application, the market is segmented into Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening and Treatment and Monitoring. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Cancer Tumor Profiling Market
The rise in cancer cases significantly drives the growth of the global cancer tumor profiling market. This increase in cancer prevalence is influenced by several factors, including an aging population, population growth, and shifts in the incidence of various cancer-causing elements. As cancer remains a complex and pervasive disease with various underlying causes, the growing burden necessitates advanced profiling techniques to enhance diagnosis, treatment, and patient outcomes. The urgent need for tailored therapeutic approaches arises from this complex landscape, solidifying the importance of cancer tumor profiling in addressing the ongoing challenges posed by the escalating incidence of cancer worldwide.
Restraints in the Global Cancer Tumor Profiling Market
Challenges related to technical issues in sample collection and storage present significant obstacles to the growth of the global cancer tumor profiling market. While personalized medicine is rapidly evolving and transforming disease identification, classification, and treatment in healthcare, these advancements are hampered by inconsistent sample management processes. As this more tailored approach to treatment becomes integrated into standard clinical practices, its impact on oncology is undeniable. However, the risks associated with sample handling and storage could impede the progress and acceptance of these innovations, ultimately affecting the overall development of the cancer tumor profiling sector.
Market Trends of the Global Cancer Tumor Profiling Market
The Global Cancer Tumor Profiling market is witnessing a significant trend driven by the integration of omics data and advancements in liquid biopsy technologies, projected to exhibit the highest CAGR during the forecast period. This shift aligns with the rising prominence of personalized medicine, transforming disease diagnosis, classification, and treatment. As tailored therapies become a standard in clinical practice, particularly within oncology, the market is evolving to accommodate innovative diagnostic tools and targeted treatment approaches. The convergence of advanced analytics and molecular profiling is revolutionizing cancer care, fostering early detection and improved patient outcomes across the globe.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Cancer Tumor Profiling Market Size by Cancer type & CAGR (2025-2032)
Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Other Cancer
Global Cancer Tumor Profiling Market Size by Biomarker type & CAGR (2025-2032)
Market Overview
Genomic Biomarker
Protein Biomarker
Global Cancer Tumor Profiling Market Size by Technology & CAGR (2025-2032)
Market Overview
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
Mass Spectrometry
In-Situ Hybridization
Microarrays
Others
Global Cancer Tumor Profiling Market Size by Technique & CAGR (2025-2032)
Market Overview
Genomics
Proteomics
Metabolomics
Epigenetics
Global Cancer Tumor Profiling Market Size by Application & CAGR (2025-2032)
Market Overview
Research
Biomarker Discovery
Personalized Medicine
Clinical Application
Diagnostics
Prognostics
Screening
Treatment and Monitoring
Global Cancer Tumor Profiling Market Size & CAGR (2025-2032)
North America (Cancer type, Biomarker type, Technology, Technique, Application)
US
Canada
Europe (Cancer type, Biomarker type, Technology, Technique, Application)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Cancer type, Biomarker type, Technology, Technique, Application)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Cancer type, Biomarker type, Technology, Technique, Application)
Brazil
Rest of Latin America
Middle East & Africa (Cancer type, Biomarker type, Technology, Technique, Application)
